Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease-Reference-Cited by-同舟云学术

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

Published:2018-01-23 Issue:4 Volume:137 Page:338-350
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Bonaca Marc P.¹,Nault Patrice²,Giugliano Robert P.¹,Keech Anthony C.³,Pineda Armando Lira⁴,Kanevsky Estella¹,Kuder Julia¹,Murphy Sabina A.,Jukema J. Wouter⁵,Lewis Basil S.⁶,Tokgozoglu Lale⁷,Somaratne Ransi⁴,Sever Peter S.⁸,Pedersen Terje R.⁹,Sabatine Marc S.¹

Affiliation:

1. Thrombolysis In Myocardial Infarction Study Group, Brigham and Women’s Hospital Heart & Vascular Center, Boston, MA (M.P.B., R.P.G., E.K., J.K., M.S.S.)

2. McGill University, Montreal, and Division of Vascular and Endovascular Surgery, Centre Intégré de la santé et des services sociaux de l’Outaouais, Gatineau, Canada (P.N.)

3. Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia (A.C.K.)

4. Amgen, Thousand Oaks, CA (A.L.P., R.S.)

5. Department of Cardiology, Leiden University Medical Center, the Netherlands (J.W.J.)

6. Lady Davis Carmel Medical Center and Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel (B.S.L.)

7. Department of Cardiology, Hacettepe University, Ankara, Turkey (L.T.)

8. International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, UK (P.S.S.)

9. Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Norway (T.R.P.)

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference38 articles.

1. Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry

2. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease

3. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS) [published online ahead of print August 26, 2017].;Aboyans V;Eur Heart J

4. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Cited by 730 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-target lesion progression: Unveiling critical predictors and outcomes in patients with in-stent restenosis;International Journal of Cardiology;2024-12

2. Advancements in Omics and Breakthrough Gene Therapies: A Glimpse into the Future of Peripheral Artery Disease;Annals of Vascular Surgery;2024-10

3. Medical Optimization of Patients with Symptomatic Peripheral Arterial Disease;Annals of Vascular Surgery;2024-10

4. Clinical Outcomes of Non–Stent-Based Interventions for Symptomatic Below-the-Knee Peripheral Artery Disease in the Excellence in Peripheral Artery Disease (XLPAD) Registry;The American Journal of Cardiology;2024-10

5. Antithrombotic Strategies for Patients With Peripheral Artery Disease;Journal of the American College of Cardiology;2024-09